Cancer drug developer Tesaro entered the hot immuno-oncology space with an exclusive, worldwide license and collaboration agreement for antibodies from AnaptysBio that target three different immune checkpoint receptors.
Tesaro's stock closed up 27.5% at $38.86 per share after the Waltham, Massachusetts-based company announced its advance into the cancer...